Methotrexate Sodium Injection Shortage
Last Updated: September 16, 2025
Status: Current
Unavailable, Current:
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (Accord Healthcare Inc.)
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (Teva Pharmaceuticals USA, Inc.)
Limited Availability, Current:
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (Teva Pharmaceuticals USA, Inc.)
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (Hospira, Inc., a Pfizer Company)
Available, Current:
- Methotrexate Preservative Free, Injection, 1 g (Fresenius Kabi USA, LLC)
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (Hospira, Inc., a Pfizer Company)
- Methotrexate Sodium, Injection, 25 mg/1 mL (Fresenius Kabi USA, LLC)
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (Hospira, Inc., a Pfizer Company)
- Methotrexate, Preservative Free, Injection, 1 g (Hikma Pharmaceuticals USA, Inc.)
- Methotrexate, Preservative Free, Injection, 25 mg/1 mL (Hikma Pharmaceuticals USA, Inc.)
To Be Discontinued:
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (Teva Pharmaceuticals USA, Inc.)
NDC Code: 0703-3678-01Availability: Unavailable
Status: Current
Date of update: September 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Estimated recovery: January 2026
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 800-545-8800
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (Accord Healthcare Inc.)
NDC Code: 16729-277-30Availability: Unavailable
Status: Current
Date of update: September 16, 2025
Update type: Reverified
Reason for shortage: Shortage of an active ingredient
Related Information: Resupply: estimated 21 days
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 866-941-7875, option 2
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (Accord Healthcare Inc.)
NDC Code: 16729-277-35Availability: Unavailable
Status: Current
Date of update: September 16, 2025
Update type: Reverified
Reason for shortage: Shortage of an active ingredient
Related Information: Resupply: estimated 21 days
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 866-941-7875, option 2
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (Teva Pharmaceuticals USA, Inc.)
NDC Code: 0703-3671-01Availability: Limited Availability
Status: Current
Date of update: September 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Estimated recovery: October 2025
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 800-545-8800
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (Teva Pharmaceuticals USA, Inc.)
NDC Code: 0703-3675-01Availability: Limited Availability
Status: Current
Date of update: September 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Estimated recovery: October 2025
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 800-545-8800
Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (Hospira, Inc., a Pfizer Company)
NDC Code: 61703-350-10Availability: Limited Availability
Status: Current
Date of update: August 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 844-646-4398
Methotrexate Preservative Free, Injection, 1 g (Fresenius Kabi USA, LLC)
NDC Code: 63323-122-50Availability: Available
Status: Current
Date of update: September 2, 2025
Update type: Reverified
Related Information: Check wholesaler for inventory
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 888-386-1300
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (Hospira, Inc., a Pfizer Company)
NDC Code: 61703-408-41Availability: Available
Status: Current
Date of update: August 15, 2025
Update type: Reverified
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 844-646-4398
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (Hospira, Inc., a Pfizer Company)
NDC Code: 61703-408-25Availability: Available
Status: Current
Date of update: August 15, 2025
Update type: Reverified
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 844-646-4398
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (Hospira, Inc., a Pfizer Company)
NDC Code: 61703-124-40Availability: Available
Status: Current
Date of update: August 15, 2025
Update type: Reverified
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 844-646-4398
Methotrexate Sodium, Injection, 25 mg/1 mL (Fresenius Kabi USA, LLC)
NDC Code: 63323-123-10Availability: Available
Status: Current
Date of update: September 2, 2025
Update type: Reverified
Related Information: Check whlolesaler for inventory
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 888-386-1300
Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (Hospira, Inc., a Pfizer Company)
NDC Code: 61703-350-38Availability: Available
Status: Current
Date of update: August 15, 2025
Update type: Reverified
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 844-646-4398
Methotrexate, Preservative Free, Injection, 1 g (Hikma Pharmaceuticals USA, Inc.)
NDC Code: 0143-9830-01Availability: Available
Status: Current
Date of update: July 23, 2025
Update type: Reverified
Related Information: Currently available. Additional product will be made available as it is released.
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 800-631-2174
Methotrexate, Preservative Free, Injection, 25 mg/1 mL (Hikma Pharmaceuticals USA, Inc.)
NDC Code: 0143-9519-10Availability: Available
Status: Current
Date of update: July 23, 2025
Update type: Reverified
Related Information: Additional lots are scheduled to be manufactured. Product will be made available as it is released.
Therapeutic category: Rheumatology; Oncology
Initial posting date: March 13, 2023
Contact info: 800-631-2174
Injection, 25 mg/1 mL (Hospira, Inc., a Pfizer Company)
NDC Code: 61703-161-05Status: To Be Discontinued
Date of update: January 8, 2025
Update type: New
Related Information: Discontinuation of the manufacture of the drug
Therapeutic category: Oncology; Rheumatology
Date discontinued: January 8, 2025
Initial posting date: January 8, 2025
Contact info: 844-646-4398
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.